Advice
Following a full submission
telbivudine (Sebivo®) is accepted for use within NHS Scotland for the treatment of chronic hepatitis B in adult patients with compensated liver disease and evidence of viral replication, persistently elevated serum alanine aminotransferase levels and histological evidence of active inflammation and/or fibrosis.
For a number of therapeutic endpoints telbivudine proved to be equivalent or superior to a comparator nucleoside reverse transcriptase inhibitor.
Download detailed advice90KB (PDF)
Medicine details
- Medicine name:
- telbivudine (Sebivo)
- SMC ID:
- 438/08
- Indication:
- For the treatment of chronic hepatitis B in adult patients with compensated liver disease and evidence of viral replications
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 February 2008